
Validea's analysis indicates Humana (HUM), a large-cap healthcare growth stock, achieved an 81% rating using its Multi-Factor Investor model, based on Pim van Vliet's strategy. This model prioritizes low volatility, strong momentum, and high net payout yields, with the 81% score signifying 'some interest' in HUM according to Validea's methodology, aligning it with a conservative factor investing approach.
Humana Inc. (HUM) presents a mixed profile according to Validea's quantitative analysis using the Pim van Vliet multi-factor model. The stock scores a moderately high 81%, indicating some alignment with the strategy's focus on low volatility, strong momentum, and high net payout yield. Specifically, HUM passes the criteria for market capitalization and standard deviation, confirming its low-volatility characteristic, which is the cornerstone of van Vliet's investment philosophy. However, the analysis reveals weaknesses in other key areas, with HUM receiving a 'NEUTRAL' rating for both 'Twelve Minus One Momentum' and 'Net Payout Yield'. Critically, despite the 81% score, the stock's 'FINAL RANK' is a 'FAIL', suggesting that its neutral performance on momentum and yield is significant enough to disqualify it from meeting the strategy's aggregate requirements. This discrepancy highlights that while HUM exhibits some desirable conservative traits, it does not fully satisfy the multi-factor criteria for a 'buy' signal under this specific model.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment